Pharmacokinetic and clinical safety interaction study between roflumilast 500 μg repeated dose and midazolam (single dose, i.v. 1 mg, oral 2 mg alone and with roflumilast) in healthy male subjects; open, randomized, five periods cross-over study with interspersed fixed treatment periods

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

An open-label, randomized, five-period crossover study in healthy male subjects.